Other Titles
Global Concerns for Cancer Clinical Trials
Abstract
Purpose: To understand the current informed consent process in cancer clinical trials in Taiwan.
Methods: Using semi-structured interview guides to interview clinical research nurses and cancer patients. Content analysis was used to analysis the data.
Results: 10 clinical research nurses and 10 cancer patients were interviewed from three medical centers in Taiwan. From clinical research nurses' practice, informed consent of cancer clinical trials normally happen on a very stressful situation for patients after they were informed bad news regarding their cancer progression by physicians. If the patient is not ready for the informed consent, clinical research nurses normally explain the trial information to family members first and let family members discussed with patients. Therefore, family member is an important role in patient decision making under Taiwanese culture context. In order to achieve patient understanding, informed consent is a continuous communication process for clinical research nurses. Both clinical research nurses and patients reported that trust physician, a hope for personal benefits, no standard treatment options, financial considerations, and special care services are the main reasons for patients to enroll in a cancer clinical trial. Fear of possible risks and adverse effects of study drugs, time investment and travel, and frequent tests were repeatedly addressed as the main barriers to trial participation. More than 70% of patients reported that they made the decision to attend a trial treatment and signed the consent form directly after informed consent. Over 50% of participants mentioned that the language of the consent form was too hard to understand and after they finished reading, they still did not understand the information. Clinical research nurses indicated that patient misunderstanding/poor understanding of clinical trial, trust of recommendation from their physician and different opinions with physicians are the dilemmas of informed consent.
Conclusion: Information, comprehension and voluntariness are three essential elements of the consent process. However, our interview study indicated that patients receive a trial treatment is because they are under the pressure of disease progression and choose to trust their physician's recommendation, not based on understanding of trial information. Further research could be conducted to improve patient autonomy and understanding of cancer clinical trials.
Sigma Membership
Unknown
Type
Presentation
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
Cancer, Clinical Trial, Informed Consent
Recommended Citation
Kao, Chi-Yin and Huang, Mei-Chih, "Informed consent practice in cancer clinical trials in Taiwan" (2017). INRC (Congress). 440.
https://www.sigmarepository.org/inrc/2017/presentations_2017/440
Conference Name
28th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Dublin, Ireland
Conference Year
2017
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Informed consent practice in cancer clinical trials in Taiwan
Dublin, Ireland
Purpose: To understand the current informed consent process in cancer clinical trials in Taiwan.
Methods: Using semi-structured interview guides to interview clinical research nurses and cancer patients. Content analysis was used to analysis the data.
Results: 10 clinical research nurses and 10 cancer patients were interviewed from three medical centers in Taiwan. From clinical research nurses' practice, informed consent of cancer clinical trials normally happen on a very stressful situation for patients after they were informed bad news regarding their cancer progression by physicians. If the patient is not ready for the informed consent, clinical research nurses normally explain the trial information to family members first and let family members discussed with patients. Therefore, family member is an important role in patient decision making under Taiwanese culture context. In order to achieve patient understanding, informed consent is a continuous communication process for clinical research nurses. Both clinical research nurses and patients reported that trust physician, a hope for personal benefits, no standard treatment options, financial considerations, and special care services are the main reasons for patients to enroll in a cancer clinical trial. Fear of possible risks and adverse effects of study drugs, time investment and travel, and frequent tests were repeatedly addressed as the main barriers to trial participation. More than 70% of patients reported that they made the decision to attend a trial treatment and signed the consent form directly after informed consent. Over 50% of participants mentioned that the language of the consent form was too hard to understand and after they finished reading, they still did not understand the information. Clinical research nurses indicated that patient misunderstanding/poor understanding of clinical trial, trust of recommendation from their physician and different opinions with physicians are the dilemmas of informed consent.
Conclusion: Information, comprehension and voluntariness are three essential elements of the consent process. However, our interview study indicated that patients receive a trial treatment is because they are under the pressure of disease progression and choose to trust their physician's recommendation, not based on understanding of trial information. Further research could be conducted to improve patient autonomy and understanding of cancer clinical trials.